Can a simple infusion shield kidney transplants from a dangerous virus?

NCT ID NCT07096453

Recruiting now Disease control Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a drug called Cytogam (CMVIG) can prevent cytomegalovirus (CMV) infection in kidney transplant patients who are switching to a new immunosuppressant. The researchers will measure antibody levels in 30 adult patients over 8 weeks to see how the drug works in the body. The goal is to find a better way to protect transplant recipients from this common and serious infection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cytogam (CMVIG)
What this could lead to: If it works, this could point toward a way to prevent CMV infection in kidney transplant patients, reducing complications.
What could go wrong: This is a small early-phase pilot study with only 30 participants, so results may not apply broadly. It is testing antibody levels, not directly proving infection prevention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CMV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CMV KIDNEY TRANSPLANT; COMPLICATIONS

Contacts and locations

Locations

University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.